1,2,9,9a-Tetrahydro-fluoren-3-on | 4590-03-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: 1,2,9,9a-Tetrahydro-fluoren-3-on
• 英文别名: 1,2,3,9a-Tetrahydro-fluorenon-(3)；1,9a-Dihydrofluoren-3(2H)-on；1,2,3,9a-Fluoren-3-on；1,2,9,9a-tetrahydro-fluoren-3-one；1,2,9,9a-tetrahydro-3H-fluoren-3-one；1,2,9,9a-tetrahydrofluoren-3-one
• CAS: 4590-03-8
• 化学式: C₁₃H₁₂O
• 分子量: 184.238
• InChiKey: JROFGDQDOURIRX-UHFFFAOYSA-N

物化性质

• 熔点：
  96 °C
• 沸点：
  331.0±17.0 °C(Predicted)
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1,2,9,9a-Tetrahydro-fluoren-3-on 在 palladium on activated charcoal 芴 、 hydroxide 作用下， 生成 3-methoxy-9H-fluorene
  参考文献：
  名称：

  致癌物的Omicron-甲氧基衍生物N-2-芴基乙酰胺。潜在的潜在生物芳构剂。

  摘要：

  DOI：

  10.1021/jm00323a018
• 作为产物：
  描述：

  2-碘苯甲基溴 在 盐酸 、 六甲基磷酰三胺 、 lithium aluminium tetrahydride 、 四(三苯基膦)钯 、 三乙胺 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 22.0h， 生成 1,2,9,9a-Tetrahydro-fluoren-3-on
  参考文献：
  名称：

  Metal-promoted cyclization. 21. Palladium-catalyzed procedures for [3 + 2] annulation via intramolecular alkenylpalladation and arylpalladation

  摘要：

  DOI：

  10.1021/jo00258a050

文献信息

• Estrogen receptor modulators
  申请人：——

  公开号：US20030027840A1

  公开（公告）日：2003-02-06

  The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restinosis, gynacomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.

  本发明涉及化合物及其衍生物、它们的合成方法以及它们作为雌激素受体调节剂的应用。本发明的化合物是雌激素受体的配体，因此可用于治疗或预防与雌激素功能相关的多种疾病，包括：骨丢失、骨折、骨质疏松症、软骨退化、子宫内膜异位症、子宫纤维瘤病、热潮红、LDL胆固醇水平升高、心血管疾病、认知功能损害、脑部退行性疾病、再狭窄、男性乳房发育、血管平滑肌细胞增殖、肥胖、失禁以及癌症，尤其是乳腺癌、子宫癌和前列腺癌。
• Synthesis of Indeno[1,2-<i>d</i>]azepine Derivatives
  作者：Masaru Kimura、Kyosuke Satake、Shigeaki Yonemori、Shiro Morosawa

  DOI：10.1246/bcsj.53.3232

  日期：1980.11

  4-Ethoxyindeno[1,2-d]azepine(18) and 10-bromo-4-ethoxyindeno[1,2-d]azepine were prepared by O-ethylation of indeno[1,2-d]azepin-4-ol(12ab) and 10-bromoindeno[1,2-d]azepin-4-ol(13ab) with Et3OBF4 in 62 and 69% yields, respectively. 12ab was obtained by bromination of 1,2,3,4,5,10-hexahydro-4-indeno[1,2-d]azepine(3) or 1,2,3,4-tetrahydroindeno[1,2-d]azepin-4-one with NBS, and subsequent dehydrobromination of the corresponding bromide formed in situ on basic alumina in 10% yield. When the bromination time was over 20 h, only 13ab was isolated in 20% yield. Direct dehydrogenation of 3 with DDQ gave 10-chloroindeno[1,2-d]azepin-4-ol in 27% yield. The NMR and electronic spectra of 18 indicated the presence of a fully conjugated 14-pi ring system in it. We also investigated the possibility for dehydrogenation of 3-ethoxycarbonyl-1,2,3,4,5,5a,10,10a-octahydroindeno [1,2-d] azepin-10-one.

  4-乙氧基吲哚[1,2-d]阿扎平(18)和10-溴-4-乙氧基吲哚[1,2-d]阿扎平通过用Et3OBF4对吲哚[1,2-d]阿扎平-4-醇(12ab)和10-溴吲哚[1,2-d]阿扎平-4-醇(13ab)进行O-乙基化制备，产率分别为62%和69%。12ab是通过用NBS对1,2,3,4,5,10-六氢-4-吲哚[1,2-d]阿扎平(3)或1,2,3,4-四氢吲哚[1,2-d]阿扎平-4-酮进行溴化反应得到的，随后在碱性铝土矿上对相应的原位形成的溴化物进行脱溴反应，产率为10%。当溴化时间超过20小时时，仅获得了20%产率的13ab。用DDQ对3进行直接脱氢反应得到10-氯吲哚[1,2-d]阿扎平-4-醇，产率为27%。18的NMR和电子光谱表明其存在一个完全共轭的14-π环体系。我们还研究了3-乙氧羧基-1,2,3,4,5,5a,10,10a-八氢吲哚[1,2-d]阿扎平-10-酮的脱氢可能性。
• The synthesis and ionisation constants of some fluorenamines
  作者：J. Davey、B. R. T. Keene、G. Mannering

  DOI：10.1039/j39670000120

  日期：——

  3-Fluorenamine and certain of its homologues may be conveniently obtained from the corresponding tetrahydrofluorenones by the Semmler–Wolff aromatisation. The ionisation constants of the fluorenamines have been determined and are discussed in terms of possible steric effects.

  可以通过Semmler-Wolff芳构化法从相应的四氢芴酮中方便地获得3-Fluorenamine及其某些同系物。已经确定了芴胺的电离常数，并根据可能的空间效应进行了讨论。
• Selective estrogen receptor modulators
  申请人：——

  公开号：US20040210080A1

  公开（公告）日：2004-10-21

  The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, metastatic bone disease, Paget s disease, periodontal disease, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.

  本发明涉及化合物及其衍生物、它们的合成以及它们作为雌激素受体调节剂的用途。本发明的化合物是雌激素受体的配体，因此可能对与雌激素功能相关的各种疾病的治疗或预防有用，包括：骨质流失、骨折、骨质疏松症、转移性骨病、帕吉特病、牙周病、软骨退化、子宫内膜异位症、子宫肌瘤、潮热、低密度脂蛋白胆固醇水平升高、心血管疾病、认知功能障碍、脑退行性疾病、再狭窄、男性乳房发育、血管平滑肌细胞增殖、肥胖、失禁以及乳腺、子宫和前列腺癌，特别是乳腺、子宫和前列腺癌的治疗。
• Orthogonal gene switches
  申请人：Ciliberto Gennaro

  公开号：US20070087346A1

  公开（公告）日：2007-04-19

  The present invention relates to an orthogonal gene switch for regulating the expression of a desired gene. The gene switch comprises a chimeric transcription factor that does not respond to endogenous ligands, and a ligand that is capable of activating the chimeric transcription factor but not endogenous transcription factors. The present invention also relates to the method of constructing the orthogonal gene switch.

  本发明涉及一种正交基因开关，用于调节所需基因的表达。该基因开关包括一个嵌合转录因子，不响应内源性配体，以及一种配体，能够激活嵌合转录因子，但不能激活内源性转录因子。本发明还涉及构建正交基因开关的方法。